Doripenem Injectable (Iv) Suppliers & Bulk Manufacturers
Available Forms: Injectable (IV)
Available Strengths: 500 mg, 1 g per vial
Reference Brands: Doribax(US & EU)
Category:
Antibiotics
Doripenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, causing bacterial lysis and death. It offers broad-spectrum activity against resistant gram-negative bacteria, including Pseudomonas. Benefits include rapid, effective bacterial eradication, high tissue penetration, and once-daily dosing, making it ideal for severe, hospital-based infections.
Doripenem Injectable (IV) is available in Injectable (IV)
and strengths such as 500 mg, 1 g per vial.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Doripenem Injectable (IV) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Doripenem Injectable (IV) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Doripenem injectable is approved in the EU and US for severe bacterial infections such as pneumonia, intra-abdominal, and urinary tract infections. In the EU, brands like Doribax are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We facilitate seamless market access, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing